Adrulipase alfa is under clinical development by First Wave BioPharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Adrulipase alfa’s likelihood of approval (LoA) and phase transition for Exocrine Pancreatic Insufficiency took place on 14 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Adrulipase alfa Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Adrulipase alfa overview
Adrulipase alfa is under development for the treatment of exocrine pancreatic insufficiency (EPI) in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). It is administered as a oral capsule. The therapeutic candidate is an autologous Yarrowia lipolytica recombinant lipase. It is developed based on recombinant DNA technology. It was also under development for the treatment of malabsorption syndrome.
First Wave BioPharma overview
First Wave BioPharma, formerly AzurRx BioPharma, is a development-stage biopharmaceutical company that focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development include MS1819 a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). MS1819 completed the phase IIa trial in partnership with Mayoly which is a European Pharmaceutical company. Its pre-clinical products include AZX1103 and AZX1101 which is a recombinant beta-lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. First Wave BioPharma is headquartered in Brooklyn, New York, the US.
Quick View Adrulipase alfa LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|